Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue

Clinical Cancer Research

Volumn 3, Issue 12 I, 1997, Pages 2507-2511

  Joseph, Ingrid B J K ^a   Nelson, Joel B ^a,b   Denmeade, Samuel R ^a,b   Isaacs, John T ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS; ARTICLE; CANCER GROWTH; DOSE RESPONSE; GROWTH REGULATION; HORMONAL REGULATION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR VASCULARIZATION;

ANDROGENS; ANIMALS; APOPTOSIS; DIHYDROTESTOSTERONE; ENDOTHELIAL GROWTH FACTORS; HUMANS; LYMPHOKINES; MALE; MICE; MICE, SCID; ORCHIECTOMY; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RATS; TIME FACTORS; TRANSPLANTATION, HETEROLOGOUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0031417489     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nat. Med., 1: 27-31, 1995.
2. Hanahan, D., and Folkman, J. Patterns and emerging mechanisms of angiogenic switch during tumorigenesis. Cell, 86: 353-364, 1996.
3. Furusato, M., Wakui, S., Sasaki, H., Ito, K., and Ushigome, S. Tumor angiogenesis in latent prostatic carcinoma. Br. J. Cancer, 70: 1244-1246, 1994.
4. Wakui, S., Furusato, M., Itoh, T., Sasaki, H., Ariyama, A., Kinoshita, I., Asano, K., Tokuda, T., Aizawa, S., and Ushigome, S. Tumor angiogenesis in prostatic carcinoma with and without bone marrow metastasis: a morphometric study. J. Pathol., 168: 257-262, 1992.
5. Ichikawa, T., Lamb, J. C., Christensson, P. J., Hartley-Asp, B., and Isaacs, J. T. The antitumor effect of the quinoline-3-carboxamide linomide on Dunning R-3327 rat prostatic cancers. Cancer Res., 52: 3022-3028, 1992.
6. Vukanovic, J., and Isaacs, J. T. Human prostate cancer cells are sensitive to programmed (apoptotic) death induced by an antiangiogenic agent, linomide. Cancer Res., 55: 3517-3520, 1995.
7. Vukanovic, J., Passaniti, A., Hirata, T., Traystman, R. J., Hartley-Asp, B., and Isaacs, J. T. Antiangiogenic effects of the quinoline-3-carboxamide linomide. Cancer Res., 53: 1833-1837, 1993.
8. Vukanovic, J., and Isaacs, J. T. Linomide inhibits angiogenesis, growth metastasis, and macrophage infiltration within rat prostatic cancers. Cancer Res., 55: 1499-1504, 1995.
9. Joseph, I. B. J. K., and Isaacs, J. T. The antiangiogenic agent, linomide, inhibits TNF-α secretion via inhibition of its synthesis. Prostate, 29: 183-190, 1996.
10. Joseph, I. B. J. K., Vukanovic, J., and Isaacs, J. T. Antiangiogenic treatment with linomide as chemoprevention for prostate, seminal vesicle and breast carcinogenesis in rodents. Cancer Res., 56: 3404-3408, 1996.
11. Kyprianou, N., and Isaacs, J. T. Activation of programmed cell death in rat ventral prostate following castration. Endocrinology, 122: 552-562, 1988.
12. Kyprianou, N., English, H. F., and Isaacs, J. T. Programmed cell death during regression of the PC-82 human prostate cancer following androgen ablation. Cancer Res., 50: 3748-3753, 1990.
13. Hartley-Asp, B., Vukanovic, J., Joseph, I. B. J. K., Strandgarden, K., Polacek, J., and Isaacs, J. T. Anti-angiogenic treatment with linomide as adjuvant to surgical castration in experimental prostate cancer. J. Urol., 158: 902-907, 1997.
14. Joseph, I. B. J. K., and Isaacs, J. T. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers. Cancer Res., 57: 1054-1057, 1997.
15. Horoszewicz, J. S., Leong, S. S., Kawinski, E., Karr, J. P., Rosenthal, H., Chu, M., Mirand, E. A., and Murphy, G. P. LNCaP model of human prostatic carcinoma. Cancer Res., 43: 1809-1818, 1983.
16. Isaacs, J. T., Isaacs, W. B., Feitz, W. F. J., and Scheres, J. Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate, 9: 261-281, 1986.
17. Passaniti, A, Isaacs, J. T., Haney, J. A., Adler, S. W., Cujdik, T. J., and Long, P. V. Stimulation of human prostatic carcinoma tumor growth in athymic mice and control of migration in culture by extracellular matrix. Int. J. Cancer, 51: 318-324, 1992.
18. Coffey, D. S., Shimazaki, J., and Williams-Ashman, H. G. Polymerization of deoxyribonucleotides in relation to androgen-induced prostatic growth. Arch. Biochem. Biophys., 124: 184-198, 1968.
19. Furuya, Y., Lin, X. S., Walsh, J. C., Nelson W. G., and Isaacs, J. T. Androgen ablation-induced programmed death of prostatic glandular cells does not involve recruitment in a defective cell cycle or p53 induction. Endocrinology, 136: 1898-1906, 1995.
20. Lee, C., Sutkowski, D. M., Sensibar, J. A., Zelner, D., Kim, I., Amsel, I., Shaw, N., Prins, G. S., and Kozlowski, J. M. Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone. Endocrinology, 136: 796-803, 1995.
21. Brown, L. F., Yeo, K-T., Berse, B., Morgentaler, A., Dvorak, H. F., and Rosen, S. Vascular permeability factor (vascular endothelial growth factor) is strongly expressed in the normal male genital tract and is present in substantial quantities in semen. J. Urol., 154: 576-579, 1995.
22. Moon, W-C., Choi, I. R., and Moon, S. Y. Endocrine therapy inhibits expression of vascular endothelial growth factor and angiogenesis in prostate cancer. J. Urol., 157 (Suppl.): 223, 1997.
23. Isaacs, J. T. Hormonally responsive versus unresponsive progression of prostatic cancer to antiandrogen therapy as studied with the Dunning R-3327 AT- and -G rat adenocarcinomas. Cancer Res., 42: 5010-5014, 1982.